Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care.
Glintborg B, Kringelbach T, Bolstad N, Warren DJ, Eng G, Sørensen IJ, Loft AG, Hendricks O, Hansen I, Linauskas A, Nordin H, Kristensen S, Lindegaard H, Jensen DV, Goll GL, Høgdall E, Gehin J, Enevold C, Nielsen CH, Krogh NS, Johansen JS, Hetland ML.
Glintborg B, et al. Among authors: nielsen ch.
Scand J Rheumatol. 2018 Sep;47(5):418-421. doi: 10.1080/03009742.2017.1376110. Epub 2018 Jan 9.
Scand J Rheumatol. 2018.
PMID: 29310493
No abstract available.